HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Arkansas Prilosec OTC Coverage Offers Savings Model For Plan Sponsors

This article was originally published in The Tan Sheet

Executive Summary

An Arkansas state health plan that covers use ofPrilosec OTC provides a blueprint for plan sponsors looking to nonprescription drugs for cost savings
Advertisement

Related Content

Perrigo Pursues OTC Reimbursement Opportunity In Emerging "ORx" Space
Perrigo Pursues OTC Reimbursement Opportunity In Emerging "ORx" Space
Perrigo Pursues OTC Reimbursement Opportunity In Emerging "ORx" Space
Prilosec OTC Covered By Michigan Blues In Bid To Convert Nexium Patients
Expensive Rx Drugs Put Spotlight On OTC Opportunity – Economist
Prilosec OTC “Coverage Gap” Pitch Spotlights Medicare Payment Question
Delay In OTC Loratadine Coverage By Medicaid Caused “Lost Savings” – Study
Health Plans Initiating Coverage Of Claritin, Prilosec OTC – PBMI Survey
Prilosec OTC Switchback: Plans Should Look To OTCs For Savings, Study Says
Prilosec OTC Switchback: Plans Should Look To OTCs For Savings, Study Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS099017

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel